ArticleFrontiers in endocrinology2026
Prospective association between biological aging and risk of hospital-diagnosed MASLD: evidence from the UK Biobank.
Article in Frontiers in endocrinology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
15 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background and aims: Metabolic dysfunction-associated steatotic liver disease (MASLD) is a prevalent metabolic disorder linked to increased all-cause and cardiovascular mortality. While accelerated biological aging is a known risk factor for age-related diseases, its role in MASLD remains unclear. This study explores the association between biological aging and hospital-diagnosed MASLD and investigates the potential mediating effects of biological aging on lifestyle-MASLD relationships. Methods and results: Data were from the UK Biobank, and the biological age was estimated by PhenoAge and Klemera-Doubal method age (KDMAge). The association between biological aging and hospital-diagnosed MASLD (defined as hospital admission or death) was estimated using Cox regression. Biological aging acceleration was defined as positive residuals obtained from regressing biological age on chronological age. Mediation analyses were used to assess the potential mediating role of biological aging in the relationships between lifestyle and hospital-diagnosed MASLD. Among 247,444 participants, 3,254 developed hospital-diagnosed MASLD during a median follow-up of 13.7 years. Accelerated biological aging was significantly associated with hospital-diagnosed MASLD with hazard ratios of 1.46 (95% confidence interval, 1.35, 1.57) for PhenoAge acceleration and 1.35 (1.19, 1.53) for KDMAge acceleration. In mediation analyses, PhenoAge acceleration significantly accounted for the associations between four unhealthy lifestyle factors (smoking, drinking, poor diet, and low physical activity) and MASLD, with mediation proportions ranging from 11.4% to 25.5%, and the strongest effect observed for smoking. In contrast, KDMAge acceleration showed minimal mediation effects (≤2%). Conclusions: Accelerated biological aging was associated with hospital-diagnosed MASLD and may partially mediate the associations between unhealthy lifestyles and hospital-diagnosed MASLD. These findings support the potential relevance of biological aging in MASLD risk stratification and prevention.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.